Nordic Bioproducts Group opened the 1st ever continuous production facility of MCC in Lappeenranta Finland.

One vision.

Be the maker of the best
MCC in the world.

Central to our work is reducing the world’s reliance on virgin and fossil-based resources, achieving new circular solutions, and enabling impact at scale.

The time is now.

The Company

Born from Aalto University, we are a spin-off that is boldly charging into the future. We partner with the most forward-thinking scientists, companies, industrial leaders, and innovators to unleash the potential of cellulose, biomaterials, and biotechnologies – driving the green transition forward with passion and purpose.

From our groundbreaking, patented AaltoCellTM technology and Norratex fiber innovation – to BIG, our bio innovation garage – we collaborate to discover and develop sustainable, cellulose-based solutions for a better world.

Our dedication to innovation and sustainability drives us to push boundaries and create a positive impact in the world, one step at a time.

Our story

2018

In 2018, Aalto University embarked on a mission to commercialise its innovative AaltoCell™ technology by seeking a professional with extensive experience in SME business, particularly in starting and managing start-up companies and driving biomaterial innovations to market for global impact.

2019

In spring 2019, Olli Kähkönen, with over 20 years of expertise in entrepreneurship, innovation, product development, brand building, and commercialisation, was appointed at Aalto University. Previously, he worked as a project researcher and commercialisation manager in Professor Olli Dahl’s group.

Nordic Bioproducts Group was founded with the aim to develop scalable solutions that drive global environmental, social, and economic impact while supporting biodiversity conservation.

2020

In 2020, operative laboratory work began, leading to the establishment of a dedicated facility and marking the birth of B.I.G.

Shortly after, the team launched its first commercial R&D projects and expanded to include 10 academics committed to advancing innovative solutions.

2021

In 2021, the company started the establishing of its own MCC manufacturing alongside existing R&D and licensing activities to secure a stable, sustainable business with strong earning potential.

2022

In 2022, the MCC Production Facility project was launched with support from CMPC, Taaleri Bioteollisuus I Fund, and Business Finland. Built in collaboration with EV-consulting and Fiber-X, the facility relies on 90% refurbished equipment and runs entirely on renewable energy.

CMPC’s equity investment advanced the Norratex™ project, while Business Finland backed the pilot plant in Lappeenranta.

The team had grown to 15 academics, further expanding research and development capabilities.

2024

In April 2024, Nordic Bioproducts Group opened its first major production facility in Lappeenranta, Finland, powered by its proprietary AaltoCell™ Technology. The state-of-the-art plant, featuring the world’s first continuous production line for microcrystalline cellulose (MCC) with a capacity of up to 10,000 tons annually, operates sustainably with zero solid waste and significantly reduced resource consumption and emissions.

This milestone not only reinforces the company’s leadership in advanced cellulosic materials, but it is also expected to generate over 30 new jobs in Lappeenranta and more than €30 million in revenue once full production capacity is reached, paving the way for further growth and innovation.

Together we can make the future.

Next generation
of MCC

Discover purity and excellence like never before with our Microcrystalline Cellulose – setting new standards in quality and performance.

Better products for people, business and planet.

At the crossroads of creativity and cutting-edge technology, our solutions transcend boundaries, reaching across diverse industries – from food and pharmaceuticals to cosmetics, and more.